The hypertension of Cushing's syndrome: Controversies in the pathophysiology and focus on cardiovascular complications

Journal of Hypertension

Volumn 33, Issue 1, 2015, Pages 44-60

  Isidori, Andrea M ^a   Graziadio, Chiara ^a   Paragliola, Rosa Maria ^b   Cozzolino, Alessia ^c   Ambrogio, Alberto G ^d   Colao, Annamaria ^c   Corsello, Salvatore M ^b   Pivonello, Rosario ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Antihypertensive treatment; Blood pressure; Corticosteroids; Cushing's syndrome; Hypercortisolism; Hypertension; Metabolic syndrome; Vascular system

Indexed keywords

GLUCOCORTICOID;

ANIMAL; BLOOD; BLOOD PRESSURE; COMPLICATION; CUSHING SYNDROME; FEMALE; HUMAN; HYPERTENSION; MALE; METABOLIC SYNDROME X; PATHOPHYSIOLOGY;

ANIMALS; BLOOD PRESSURE; CUSHING SYNDROME; FEMALE; GLUCOCORTICOIDS; HUMANS; HYPERTENSION; MALE; METABOLIC SYNDROME X;

EID: 84916880339     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000415     Document Type: Review

References (146)

1. Pivonello R, De Martino MC, De LM, Lombardi G, Colao A. Cushing's syndrome. Endocrinol Metab Clin North Am 2008; 37: 135-149; ix.
2. Graversen D, Vestergaard P, Stochholm K, Gravholt CH, Jorgensen JO. Mortality in Cushing's syndrome: A systematic review and metaanalysis. Eur J Intern Med 2012; 23: 278-282.
3. Lambert JK, Goldberg L, Fayngold S, Kostadinov J, Post KD, Geer EB. Pre-dictors of mortality and long-Term outcomes in treated Cushing's disease: A study of 346 patients. J Clin Endocrinol Metab 2013; 98: 1022-1030.
4. Pivonello R, Faggiano A, Lombardi G, Colao A. The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol Metab Clin North Am 2005; 34: 327-339; viii.
5. Pivonello R, De Martino MC, De Leo M, Tauchmanovà L, Faggiano A, Lombardi G, Colao A. Cushing's syndrome: Aftermath of the cure. Arq Bras Endocrinol Metabol 2007; 51: 1381-1391.
6. Bertoia ML, Waring ME, Gupta PS, Roberts MB, Eaton CB. Implications of new hypertension guidelines in the United States. Hypertension 2012; 60: 639-644.
7. Imai Y, Abe K, Sasaki S, Minami N, Nihei M, Munakata M, et al. Altered circadian blood pressure rhythm in patients with Cushing's syndrome. Hypertension 1988; 12: 11-19.
8. Pecori GF, Toja PM, De Martin M, Maronati A, Scacchi M, Omboni S, et al. Circadian blood pressure profile in patients with active Cushing's disease and after long-Term cure. Horm Metab Res 2007; 39: 908-914.
9. Walker BR, Stewart PM, Shackleton CH, Padfield PL, Edwards CR. Deficient inactivation of cortisol by 11 beta-hydroxysteroid dehydrogenase in essential hypertension. Clin Endocrinol (Oxf) 1993; 39: 221-227.
10. Watt GC, Harrap SB, Foy CJ, Holton DW, Edwards HV, Davidson HR, et al. Abnormalities of glucocorticoid metabolism and the reninangiotensin system: A four-corners approach to the identification of genetic determinants of blood pressure. J Hypertens 1992; 10: 473-482.
11. Van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. QJM 2000; 93: 105-111.
12. Imai Y, Abe K, Sasaki S, Minami N, Munakata M, Nihei M, et al. Exogenous glucocorticoid eliminates or reverses circadian blood pressure variations. J Hypertens 1989; 7: 113-120.
13. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141: 764-770.
14. Souverein PC, Berard A, Van Staa TP, Cooper C, Egberts AC, Leufkens HG, Walker BR. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004; 90: 859-865.
15. Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999WHO/ISH guidelines. Clin Endocrinol (Oxf) 2004; 61: 768-777.
16. Valassi E, Santos A, Yaneva M, Tóth M, Strasburger CJ, Chanson P, et al. The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol 2011; 165: 383-392.
17. Devoe DJ, Miller WL, Conte FA, Kaplan SL, Grumbach MM, Rosenthal SM, et al. Long-Term outcome in children and adolescents after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 1997; 82: 3196-3202.
18. Lodish MB, Sinaii N, Patronas N, Batista DL, Keil M, Samuel J, et al. Blood pressure in pediatric patients with Cushing syndrome. J Clin Endocrinol Metab 2009; 94: 2002-2008.
19. Hassan-Smith ZK1, Sherlock M, Reulen RC, Arlt W, Ayuk J, Toogood AA, et al. Outcome of Cushing's disease following transsphenoidal surgery in a single center over 20 years. J Clin Endocrinol Metab 2012; 97: 1194-1201.
20. Feelders RA, Pulgar SJ, Kempel A, Pereira AM. The burden of Cushing's disease: Clinical and health-related quality of life aspects. Eur J Endocrinol 2012; 167: 311-326.
21. Rossi GP, Seccia TM, Maniero C, Pessina AC. Drug-related hypertension and resistance to antihypertensive treatment: A call for action. J Hypertens 2011; 29: 2295-2309.
22. Hammer F, Stewart PM. Cortisol metabolism in hypertension. Best Pract Res Clin Endocrinol Metab 2006; 20: 337-353.
23. Pecori GF, Moro M, Cavagnini F. Gender-related differences in the presentation and course of Cushing's disease. J Clin Endocrinol Metab 2003; 88: 1554-1558.
24. Giordano R, Picu A, Marinazzo E, D'Angelo V, Berardelli R, Karamouzis I, et al. Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission. Clin Endocrinol (Oxf) 2011; 75: 354-360.
25. Magiakou MA, Mastorakos G, Zachman K, Chrousos GP. Blood pressure in children and adolescents with Cushing's syndrome before and after surgical care. J Clin Endocrinol Metab 1997; 82: 1734-1738.
26. Dias R, Storr HL, Perry LA, Isidori AM, Grossman AB, Savage MO. The discriminatory value of the low-dose dexamethasone suppression test in the investigation of paediatric Cushing's syndrome. Horm Res 2006; 65: 159-162.
27. Storr HL, Isidori AM, Monson JP, Besser GM, Grossman AB, Savage MO. Prepubertal Cushing's disease is more common in males, but there is no increase in severity at diagnosis. J Clin Endocrinol Metab 2004; 89: 3818-3820.
28. Ulick S, Wang JZ, Blumenfeld JD, Pickering TG. Cortisol inactivation overload: A mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1992; 74: 963-967.
29. Saruta T, Suzuki H, Handa M, Igarashi Y, Kondo K, Senba S. Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome. J Clin Endocrinol Metab 1986; 62: 275-279.
30. Connell JM, Whitworth JA, Davies DL, Lever AF, Richards AM, Fraser R. Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man. J Hypertens 1987; 5: 425-433.
31. Ritchie CM, Sheridan B, Fraser R, Hadden DR, Kennedy AL, Riddell J, Atkinson AB. Studies on the pathogenesis of hypertension in Cushing's disease and acromegaly. Q J Med 1990; 76: 855-867.
32. Shibata H, Suzuki H, Maruyama T, Saruta T. Gene expression of angiotensin II receptor in blood cells of Cushing's syndrome. Hypertension 1995; 26 (6 Pt 1): 1003-1010.
33. Yasuda G, Shionoiri H, Umemura S, Takasaki I, Ishii M. Exaggerated blood pressure response to angiotensin II in patients with Cushing's syndrome due to adrenocortical adenoma. Eur J Endocrinol 1994; 131: 582-588.
34. Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension 2005; 46: 1227-1235.
35. Quinkler M, Stewart PM. Hypertension and the cortisol-cortisone shuttle. J Clin Endocrinol Metab 2003; 88: 2384-2392.
36. Stewart PM, Walker BR, Holder G, O'Halloran D, Shackleton CH. 11 beta-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: Explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1995; 80: 3617-3620.
37. Isidori AM, Kaltsas GA, Pozza C, et al. The ectopic adrenocorticotropin syndrome: Clinical features, diagnosis, management, and longterm follow-up. J Clin Endocrinol Metab 2006; 91: 371-377.
38. Whitworth JA, Gordon D, Andrews J, Scoggins BA. The hypertensive effect of synthetic glucocorticoids in man: Role of sodium and volume. J Hypertens 1989; 7: 537-549.
39. Williamson PM, Kelly JJ, Whitworth JA. Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans. J Hypertens Suppl 1996; 14: S37-S41.
40. Bailey MA, Mullins JJ, Kenyon CJ. Mineralocorticoid and glucocorticoid receptors stimulate epithelial sodium channel activity in a mouse model of Cushing syndrome. Hypertension 2009; 54: 890-896.
41. Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, Cutler GB, et al. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 1985; 61: 536-540.
42. McMahon EG. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr Opin Pharmacol 2001; 1: 190-196.
43. Rickard AJ, Morgan J, Bienvenu LA, Fletcher EK, Cranston GA, Shen JZ, et al. Cardiomyocyte mineralocorticoid receptors are essential for deoxycorticosterone/salt-mediated inflammation and cardiac fibrosis. Hypertension 2012; 60: 1443-1450.
44. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-Aldosterone hypertensive rats. Hypertension 2006; 47: 656-664.
45. Mannelli M, Lanzillotti R, Pupilli C, Ianni L, Conti A, Serio M. Adrenal medulla secretion in Cushing's syndrome. J Clin Endocrinol Metab 1994; 78: 1331-1335.
46. Heaney AP, Hunter SJ, Sheridan B, Brew AA. Increased pressor response to noradrenaline in pituitary dependent Cushing's syndrome. Clin Endocrinol (Oxf) 1999; 51: 293-299.
47. McKnight JA, Rooney DP, Whitehead H, Atkinson AB. Blood pressure responses to phenylephrine infusions in subjects with Cushing's syndrome. J Hum Hypertens 1995; 9: 855-858.
48. Jyotsna VP, Naseer A, Sreenivas V, Gupta N, Deepak KK. Effect of Cushing's syndrome: Endogenous hypercortisolemia on cardiovascular autonomic functions. Auton Neurosci 2011; 160: 99-102.
49. Ruschitzka F, Quaschning T, Noll G, deGottardi A, Rossier MF, Enseleit F, et al. Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: Role of nitric oxide. Circulation 2001; 103: 3129-3135.
50. Kirilov G, Tomova A, Dakovska L, Kumanov P, Shinkov A, Alexandrov AS. Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing's syndrome. Eur J Endocrinol 2003; 149: 549-553.
51. Kelly JJ, Martin A, Whitworth JA. Role of erythropoietin in cortisol-induced hypertension. J Hum Hypertens 2000; 14: 195-198.
52. Smith L, Smith JB. Regulation of sodium-calcium exchanger by glucocorticoids and growth factors in vascular smooth muscle. J Biol Chem 1994; 269: 27527-27531.
53. Radomski MW, Palmer RM, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A 1990; 87: 10043-10047.
54. Wallerath T, Witte K, Schäfer SC, Schwarz PM, Prellwitz W, Wohlfart P, et al. Down-regulation of the expression of endothelialNO synthase is likely to contribute to glucocorticoid-mediated hypertension. Proc Natl Acad Sci U S A 1999; 96: 13357-13362.
55. Simmons WW, Ungureanu-Longrois D, Smith GK, Smith TW, Kelly RA. Glucocorticoids regulate inducible nitric oxide synthase by inhibiting tetrahydrobiopterin synthesis and L-Arginine transport. J Biol Chem 1996; 271: 23928-23937.
56. Kelly JJ, Tam SH, Williamson PM, Lawson J, Whitworth JA. The nitric oxide system and cortisol-induced hypertension in humans. Clin Exp Pharmacol Physiol 1998; 25: 945-946.
57. Rizzoni D, Paiardi S, Rodella L, Porteri E, De Ciuceis C, Rezzani R, et al. Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 2638-2642.
58. Limbourg FP, Huang Z, Plumier JC, Simoncini T, Fujioka M, Tuckermann J, et al. Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids. J Clin Invest 2002; 110: 1729-1738.
59. Serarslan Y, Yönden Z, Ozgiray E, Oktar S, Güven EO, Söʇüt S, et al. Protective effects of tadalafil on experimental spinal cord injury in rats. J Clin Neurosci 2010; 17: 349-352.
60. Colao A, Pivonello R, Ferone D, Faggiano A, Facciolli G, Di Somma C, et al. Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: A randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation 2012; 125: 2323-2333.
61. Knoepfelmacher M, Pradal MJ, Dio RD, Salgado LR, Semer M, Wajchenberg BL, Liberman B. Effect of corticotrophin-releasing hormone on arginine vasopressin and atrial natriuretic factor in patients with Cushing's disease. Clin Endocrinol (Oxf) 1998; 49: 77-84.
62. Knoepfelmacher M, Pradal MJ, Dio RD, et al. Resistance to vasopressin action on the kidney in patients with Cushing's disease. Eur J Endocrinol 1997; 137: 162-166.
63. Yamaji T, Ishibashi M, Yamada A, Takaku F, Itabashi A, Katayama S, et al. Plasma levels of atrial natriuretic hormone in Cushing's syndrome. J Clin Endocrinol Metab 1988; 67: 348-352.
64. Sala C, Ambrosi B, Morganti A. Blunted vascular and renal effects of exogenous atrial natriuretic peptide in patients with cushing's disease. J Clin Endocrinol Metab 2001; 86: 1957-1961.
65. Yasunari K, Kohno M, Murakawa K, Yokokawa K, Takeda T. Glucocorticoids and atrial natriuretic factor receptors on vascular smooth muscle. Hypertension 1990; 16: 581-586.
66. Fujio N, Ohashi M, Nawata H, Kato K, Matsuo H, Ibayashi H. Cardiovascular, renal and endocrine effects of alpha-human atrial natriuretic peptide in patients with Cushing's syndrome and primary aldosteronism. J Hypertens 1989; 7: 653-659.
67. Axelrod L. Inhibition of prostacyclin production mediates permissive effect of glucocorticoids on vascular tone. Perturbations of this mechanism contribute to pathogenesis of Cushing's syndrome and Addison's disease. Lancet 1983; 1: 904-906.
68. Shimamoto K, Ura N, Nomura N, Aoyama T, Iwata M, Takagawa Y, Iimura O. Significance of renal kininases in patients with Cushing's syndrome. Clin Exp Hypertens 1995; 17: 1173-1182.
69. van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: Towards expansion of therapeutic optionš Eur J Clin Invest 2009; 39: 81-93.
70. Giordano R, Guaraldi F, Berardelli R, Karamouzis I, D'Angelo V, Marinazzo E, et al. Glucose metabolism in patients with subclinical Cushing's syndrome. Endocrine 2012; 41: 415-423.
71. Huang B, Wu P, Bowker-Kinley MM, Harris RA. Regulation of pyruvate dehydrogenase kinase expression by peroxisome proliferatoractivated receptor-Alpha ligands, glucocorticoids, and insulin. Diabetes 2002; 51: 276-283.
72. Patel R, Patel M, Tsai R, Lin V, Bookout AL, Zhang Y, et al. LXRbeta is required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice. J Clin Invest 2011; 121: 431-441.
73. van Raalte DH, Brands M, van der Zijl NJ, Muskiet MH, Pouwels PJ, Ackermans MT, et al. Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: A randomised controlled trial. Diabetologia 2011; 54: 2103-2112.
74. Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, Di Somma C, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003; 88: 2527-2533.
75. Albiger N, Testa RM, Almoto B, Ferrari M, Bilora F, Petrobelli F, et al. Patients with Cushing's syndrome have increased intimal media thickness at different vascular levels: Comparison with a population matched for similar cardiovascular risk factors. Horm Metab Res 2006; 38: 405-410.
76. Pivonello R, De Leo M, Vitale P, Cozzolino A, Simeoli C, De Martino MC, et al. Pathophysiology of diabetes mellitus in Cushing's syndrome. Neuroendocrinology 2010; 92 (Suppl 1): 77-81.
77. Giordano C, Guarnotta V, Pivonello R, Amato MC, Simeoli C, Ciresi A, et al. Is diabetes in Cushing's syndrome only a consequence of hypercortisolism? Eur J Endocrinol 2014; 170: 311-319.
78. Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 1999; 84: 2664-2672.
79. Zacharieva S, Atanassova I, Orbetzova M, Kirilov G, Nachev E, Kalinov K, Shigarminova R. Vascular endothelial growth factor (VEGF), prostaglandin E2(PGE2) and active renin in hypertension of adrenal origin. J Endocrinol Invest 2004; 27: 742-746.
80. Bender SB, McGraw AP, Jaffe IZ, Sowers JR. Mineralocorticoid receptor-mediated vascular insulin resistance: An early contributor to diabetes-related vascular disease Diabetes 2013; 62: 313-319.
81. Gatenby VK, Kearney MT. The role of IGF-1 resistance in obesity and type 2 diabetes-mellitus-related insulin resistance and vascular disease. Expert Opin Ther Targets 2010; 14: 1333-1342.
82. Parati G, Lombardi C, Hedner J, Bonsignore MR, Grote L, Tkacova R, et al. Position paper on the management of patients with obstructive sleep apnea and hypertension: Joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by the members of European COST (COoperation in Scientific and Technological research) ACTION B26 on obstructive sleep apnea. J Hypertens 2012; 30: 633-646.
83. Bottini P, Tantucci C. Sleep apnea syndrome in endocrine diseases. Respiration 2003; 70: 320-327.
84. Shipley JE, Schteingart DE, Tandon R, Starkman MN. Sleep architecture and sleep apnea in patients with Cushing's disease. Sleep 1992; 15: 514-518.
85. Venkatram S, Vakde T, Badipatla K, Niazi M, Diaz-Fuentes G. Unusual triad of obstructive sleep apnea, uncontrolled hypertension, and severe hypokalemia due to ectopic adrenocorticotropic secretion. J Bronchology Interv Pulmonol 2014; 21: 158-161.
86. Zanchetti A. What should be learnt about the management of obstructive sleep apnea in hypertension? J Hypertens 2012; 30: 669-670.
87. Schein AS, Kerkhoff AC, Coronel CC, Plentz RD, Sbruzzi G. Continuous positive airway pressure reduces blood pressure in patients with obstructive sleep; a systematic review and meta-Analysis with 1000 patients. J Hypertens 2014; 32: 1762-1773.
88. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: A metaanalysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
89. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-1357.
90. Etxabe J, Vazquez JA. Morbidity and mortality in Cushing's disease: An epidemiological approach. Clin Endocrinol (Oxf) 1994; 40: 479-484.
91. Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: Audit and meta-Analysis of literature. J Clin Endocrinol Metab 2011; 96: 632-642.
92. Dekkers OM, Horváth-Puhó E, Jørgensen JO, Cannegieter SC, Ehrenstein V, Vandenbroucke JP, et al. Multisystem morbidity and mortality in Cushing's syndrome: A cohort study. J Clin Endocrinol Metab 2013; 98: 2277-2284.
93. Carter JR, Fu Q, Minson CT, Joyner MJ. Ovarian cycle and sympathoexcitation in premenopausal women. Hypertension 2013; 61: 395-399.
94. Coylewright M, Reckelhoff JF, Ouyang P. Menopause and hypertension: An age-old debate. Hypertension 2008; 51: 952-959.
95. Zacharieva S, Orbetzova M, Stoynev A, Shigarminova R, Yaneva M, Kalinov K, et al. Circadian blood pressure profile in patients with Cushing's syndrome before and after treatment. J Endocrinol Invest 2004; 27: 924-930.
96. Assié G, Libé R, Espiard S, Rizk-Rabin M, Guimier A, Luscap W, et al. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome. N Engl J Med 2013; 369: 2105-2114.
97. Gagliardi L, Schreiber AW, Hahn CN, Feng J, Cranston T, Boon H, et al. ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia. J Clin Endocrinol Metab 2014; 99: E1784-1792.
98. Varughese AG, Nimkevych O, Uwaifo GI. Hypercortisolism in obesity-Associated hypertension. Curr Hypertens Rep 2014; 16: 443.
99. Muiesan ML, Lupia M, Salvetti M, Grigoletto C, Sonino N, Boscaro M, et al. Left ventricular structural and functional characteristics in Cushing's syndrome. J Am Coll Cardiol 2003; 41: 2275-2279.
100. Toja PM, Branzi G, Ciambellotti F, Radaelli P, De Martin M, Lonati LM, et al. Clinical relevance of cardiac structure and function abnormalities in patients with Cushing's syndrome before and after cure. Clin Endocrinol (Oxf) 2012; 76: 332-338.
101. Ainscough JF, Drinkhill MJ, Sedo A, Turner NA, Brooke DA, Balmforth AJ, Ball SG. Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction. Cardiovasc Res 2009; 81: 592-600.
102. Mihailidou AS, Loan Le TY, Mardini M, Funder JW. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 2009; 54: 1306-1312.
103. Yiu KH, Marsan NA, Delgado V, Biermasz NR, Holman ER, Smit JW, et al. Increased myocardial fibrosis and left ventricular dysfunction in Cushing's syndrome. Eur J Endocrinol 2012; 166: 27-34.
104. Alexandraki KI, Kaltsas GA, Vouliotis AI, Papaioannou TG, Trisk L, Zilos A, et al. Specific electrocardiographic features associated with Cushing's disease. Clin Endocrinol (Oxf) 2011; 74: 558-564.
105. Fallo F, Maffei P, Dalla Pozza A, Carli M, Della Mea P, Lupia M, et al. Cardiovascular autonomic function in Cushing's syndrome. J Endocrinol Invest 2009; 32: 41-45.
106. De Leo M, Pivonello R, Auriemma RS, Cozzolino A, Vitale P, Simeoli C, et al. Cardiovascular disease in Cushing's syndrome: Heart versus vasculature. Neuroendocrinology 2010; 92 (Suppl 1): 50-54.
107. Akaza I, Yoshimoto T, Tsuchiya K, Hirata Y. Endothelial dysfunction aassociated with hypercortisolism is reversible in Cushing's syndrome. Endocr J 2010; 57: 245-252.
108. Baykan M, Erem C, Gedikli O, Hacihasanoglu A, Erdogan T, Kocak M, et al. Impairment of flow-mediated vasodilatation of brachial artery in patients with Cushing's Syndrome. Endocrine 2007; 31: 300-304.
109. Prázný M, Jezková J, Horová E, Lazárová V, Hána V, Kvasnicka J, et al. Impaired microvascular reactivity and endothelial function in patients with Cushing's syndrome: Influence of arterial hypertension. Physiol Res 2008; 57: 13-22.
110. Molnar GA, Lindschau C, Dubrovska G, Mertens PR, Kirsch T, Quinkler M, et al. Glucocorticoid-related signaling effects in vascular smooth muscle cells. Hypertension 2008; 51: 1372-1378.
111. van den Meiracker AH, Batenburg WW. Corticosteroid-dependent, aldosterone-independent mineralocorticoid-receptor activation in the heart. J Hypertens 2008; 26: 1307-1309.
112. Koh JM, Kim JY, Chung YE, Park JY, Shong YK, Hong SK, et al. Increased urinary albumin excretion in Cushing's syndrome: Remission after correction of hypercortisolaemia. Clin Endocrinol (Oxf) 2000; 52: 349-353.
113. Faggiano A, Pivonello R, Melis D, Alfieri R, Filippella M, Spagnuolo G, et al. Evaluation of circulating levels and renal clearance of natural amino acids in patients with Cushing's disease. J Endocrinol Invest 2002; 25: 142-151.
114. Faggiano A, Pivonello R, Melis D, Filippella M, Di Somma C, Petretta M, et al. Nephrolithiasis in Cushing's disease: Prevalence, etiopathogenesis, and modification after disease cure. J Clin Endocrinol Metab 2003; 88: 2076-2080.
115. Biller BM, Sheppard M. The Network for the Enhancement of Endocrinology and Oncology Knowledge: A case-based consideration of current practice in Cushing's disease and acromegaly. Best Pract Res Clin Endocrinol Metab 2009; 23 (Suppl 1): S1-S4.
116. Hammer GD, Tyrrell JB, Lamborn KR, Applebury CB, Hannegan ET, Bell S, et al. Transsphenoidal microsurgery for Cushing's disease: Initial outcome and long-Term results. J Clin Endocrinol Metab 2004; 89: 6348-6357.
117. Lindholm J, Juul S, Jørgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, et al. Incidence and late prognosis of cushing's syndrome: A population-based study. J Clin Endocrinol Metab 2001; 86: 117-123.
118. Chow JT, Thompson GB, Grant CS, Farley DR, Richards ML, Young WF Jr. Bilateral laparoscopic adrenalectomy for corticotrophindependent Cushing's syndrome: A review of the Mayo Clinic experience. Clin Endocrinol (Oxf) 2008; 68: 513-519.
119. Bassareo PP, Marras AR, Pasqualucci D, Mercuro G. Increased arterial rigidity in children affected by Cushing's syndrome after successful surgical cure. Cardiol Young 2010; 20: 610-614.
120. Nieman LK. Medical therapy of Cushing's disease. Pituitary 2002; 5: 77-82.
121. Pecori Giraldi F, Ambrogio AG, Andrioli M, Sanguin F, Karamouzis I, Corsello SM, et al. Potential role for retinoic acid in patients with Cushing's disease. J Clin Endocrinol Metab 2012; 97: 3577-3583.
122. Verhelst JA, Trainer PJ, Howlett TA, Perry L, Rees LH, Grossman AB, et al. Short and long-Term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf) 1991; 35: 169-178.
123. Donadille B, Groussin L, Waintrop C, Abbas H, Tenenbaum F, Dugué MA, et al. Management of Cushing's syndrome due to ectopic adrenocorticotropin secretion with 1, ortho-1, para'-dichlorodiphenyl-dichloro-ethane: Findings in 23 patients from a single center. J Clin Endocrinol Metab 2010; 95: 537-544.
124. Pivonello R, De Martino MC, Cappabianca P, De Leo M, Faggiano A, Lombardi G, et al. The medical treatment of Cushing's disease: Effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 2009; 94: 223-230.
125. Pivonello R, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, et al. Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: Results from a Phase III study. Clin Endocrinol (Oxf) 2014; 81: 408-417.
126. Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med 2012; 366: 914-924.
127. Feelders RA, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N Engl J Med 2010; 362: 1846-1848.
128. Bertagna X, Pivonello R, Fleseriu M, Zhang Y, Robinson P, Taylor A, et al. LCI699, a potent 11beta-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: Results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab 2014; 99: 1375-1383.
129. Castinetti F, Brue T, Conte-Devolx B. The use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndrome. Curr Opin Endocrinol Diabetes Obes 2012; 19: 295-299.
130. Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab 2012; 97: 2039-2049.
131. Fallo F, Paoletta A, Tona F, Boscaro M, Sonino N. Response of hypertension to conventional antihypertensive treatment and/or steroidogenesis inhibitors in Cushing's syndrome. J Intern Med 1993; 234: 595-598.
132. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A. Target blood pressure in elderly hypertensive patients and in patients with diabetes mellitus. J Hypertens 2014; 32: 1551-1552.
133. Giugliano D, Ceriello A, Esposito K. The effects of diet on inflammation: Emphasis on the metabolic syndrome. J Am Coll Cardiol 2006; 48: 677-685.
134. da MF, Murray C, Ezzat S. Overt immune dysfunction after Cushing's syndrome remission: A consecutive case series and review of the literature. J Clin Endocrinol Metab 2011; 96: E1670-E1674.
135. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palù C, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-Term trial. Circulation 2002; 106: 2422-2427.
136. Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: A metaanalysis. J Am Med Assoc 2011; 305: 913-922.
137. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
138. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.
139. Greenberg A. Diuretic complications. Am J Med Sci 2000; 319: 10-24.
140. Mason JM, Dickinson HO, Nicolson DJ, Campbell F, Ford GA, Williams B. The diabetogenic potential of thiazide-Type diuretic and betablocker combinations in patients with hypertension. J Hypertens 2005; 23: 1777-1781.
141. Wolfgram DF, Gundu V, Astor BC, Jhagroo RA. Hydrochlorothiazide compared to chlorthalidone in reduction of urinary calcium in patients with kidney stones. Urolithiasis 2013; 41: 315-322.
142. Vigen R, Weideman RA, Reilly RF. Thiazides diuretics in the treatment of nephrolithiasis: Are we using them in an evidence-based fashion? Int Urol Nephrol 2011; 43: 813-819.
143. Chapman N, Chang CL, Dahlof B, Sever PS, Wedel H, Poulter NR. Effect of doxazosin gastrointestinal therapeutic system as thirdline antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation 2008; 118: 42-48.
144. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): A multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
145. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3-10.
146. Laurent S, Schlaich M, Esler M. New drugs, procedures, and devices for hypertension. Lancet 2012; 380: 591-600.